rEVO Biologics, an LFB Company, Announces Completion of a Dose Ranging Study of a Novel, Recombinant Form of Factor VIIa in Patients With Hemophilia A and B
6/11/2013 10:08:06 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics, an LFB Company, announced today that it has completed the treatment and follow up phase of a key dose ranging study of LR769, a novel recombinant form of human Factor VIIa (rhFVIIa), in patients with congenital hemophilia A or B. Results from the study will be presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH), which takes place June 29–July 4, 2013, in Amsterdam, The Netherlands.
Help employers find you! Check out all the jobs and post your resume.
comments powered by